VYNE Therapeutics Inc.
VYNE | NASDAQ
$28.56
$0.00 (0.00%)
Nov 2, 2026, 9:58 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 | Q3 2022 Sep 30, 2022 | Q2 2022 Jun 30, 2022 | Q1 2022 Mar 31, 2022 | Q4 2021 Dec 31, 2021 | Q3 2021 Sep 30, 2021 | Q2 2021 Jun 30, 2021 | Q1 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 955K | 454K | 570K | 524K | 476K | 605K | 501K | 493K | 486K | 423K | 424K | 354K | 407K | 398K | 477K | 2.76M | 2.73M | 2.9M | 2.95M | 4.94M | 8.08M | 19.47M |
Cost of Revenue | 6K | 6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 903K | 931K | 959K | 959K | 590K | 933K | 1.12M |
Gross Profit | 949K | 448K | 570K | 524K | 476K | 605K | 501K | 493K | 486K | 423K | 424K | 354K | 407K | 398K | 477K | 1.86M | 1.8M | 1.94M | 1.99M | 4.35M | 7.15M | 18.35M |
Operating Income | -46.58M | -24.37M | -29.75M | -37.3M | -42.6M | -45.45M | -43.64M | -37.7M | -30.84M | -30.76M | -29.26M | -30.41M | -33.51M | -31.48M | -34.3M | -14.27M | -15.7M | -16.96M | -18.02M | 453.04M | 487.3M | 329.66M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 4K | 46K |
Pretax Income | -42.7M | -21.71M | -26.73M | -33.79M | -38.52M | -42.17M | -39.8M | -33.95M | -27.86M | -28.5M | -27.87M | -29.47M | -32.65M | -30.85M | -33.93M | -38.2M | -43.22M | -45.67M | -47.86M | -59.02M | -69.46M | -226.47M |
Net Income | -42.19M | -21.46M | -26.48M | -33.67M | -38.55M | -42.2M | -39.83M | -34M | -28.43M | -29.08M | -28.45M | -32.21M | -35.08M | -33.5M | -23.21M | -24.84M | -36.66M | -48.11M | -73.33M | -84.94M | -88.37M | -235.89M |
Selling & General & Admin | 19.24M | 10.89M | 11.08M | 11.88M | 12.14M | 12.7M | 13.19M | 13.91M | 13.97M | 13.91M | 13.38M | 13.2M | 14.13M | 15.21M | 16.39M | 20.87M | 21.88M | 22.33M | 23.65M | 33.35M | 48.16M | 69.86M |
Research & Development | 28.29M | 13.93M | 19.24M | 25.95M | 30.94M | 33.36M | 30.95M | 24.29M | 17.36M | 17.28M | 16.31M | 17.56M | 19.79M | 16.67M | 18.38M | 19.34M | 19.71M | 20.65M | 20.46M | 23.06M | 23.76M | 31.84M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1 | 1 | -24.09M | -24.09M | -24.09M | -24.09M | -505.09M | -552.07M | -413M |
Operating Expenses | 47.53M | 24.82M | 30.32M | 37.83M | 43.08M | 46.06M | 44.14M | 38.19M | 31.33M | 31.19M | 29.68M | 30.77M | 33.92M | 31.88M | 34.77M | 16.13M | 17.5M | 18.9M | 20.01M | -448.68M | -480.15M | -311.31M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 3.47M | 4.55M | 5.61M | 6.69M | 4.45M | 4.45M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 47.53M | 24.82M | 30.32M | 37.83M | 43.08M | 46.06M | 44.14M | 38.19M | 31.33M | 31.19M | 29.68M | 30.77M | 33.92M | 31.88M | 34.77M | 17.03M | 18.43M | 19.85M | 20.97M | -448.09M | -479.22M | -310.19M |
Income Tax Expense | 8K | 4K | 4K | 4K | 4K | 4K | 4K | n/a | n/a | n/a | n/a | 13K | 13K | 13K | 13K | -448K | -448K | -448K | -448K | n/a | 1K | -258K |
Shares Outstanding (Basic) | 42.77K | 855.36K | 855.36K | 854.9K | 855.18K | 853.46K | 851.76K | 851.74K | 851.72K | 851.62K | 621K | 65.6K | 65.4K | 65.2K | 59.7K | 64.36K | 64.36K | 61.54K | 59.47K | 57.81K | 57.12K | 54.3K |
Shares Outstanding (Diluted) | 42.77K | 855.36K | 855.36K | 854.9K | 855.18K | 853.46K | 851.76K | 851.74K | 851.72K | 851.62K | 621K | 65.6K | 65.4K | 65.2K | 59.7K | 64.36K | 64.36K | 61.54K | 59.47K | 57.81K | 57.12K | 54.3K |
EPS (Basic) | -636.98 | -24.19 | -30 | -39 | -45 | -49.50 | -47 | -43 | -129 | -272 | -350.50 | -470.50 | -517 | -494.50 | -332.50 | -397 | -618 | -835.50 | -1.29K | -1.52K | -1.69K | -5.68K |
EPS (Diluted) | -636.98 | -24.19 | -30 | -39 | -45 | -49.50 | -47 | -43 | -129 | -272 | -350.50 | -470.50 | -517 | -494.50 | -332.50 | -397 | -618 | -835.50 | -1.29K | -1.52K | -1.69K | -5.68K |
EBITDA | -45.7M | -21.69M | -26.71M | -33.77M | -38.51M | -41.16M | -38.8M | -32.94M | -26.84M | -28.36M | -27.69M | -29.27M | -32.3M | -30.61M | -33.69M | -37.95M | -39.64M | -41M | -42.08M | -52.1M | -64.88M | -221.83M |
EBIT | -45.72M | -21.71M | -26.73M | -33.79M | -38.52M | -42.17M | -39.8M | -33.95M | -27.86M | -28.5M | -27.87M | -29.47M | -32.65M | -30.85M | -33.93M | -38.2M | -39.75M | -41.13M | -42.19M | -52.27M | -65.09M | -222.1M |
Depreciation & Amortization | 17K | 23K | 23K | 18K | 12K | 1.01M | 1M | 1M | 1.02M | 140.09K | 181.67K | 199.67K | 352.67K | 242.58K | 245K | 253K | 110K | 126K | 109K | 170K | 209K | 275K |
Add to Watchlist
Select watchlists to add or remove VYNE